ScandiBio Therapeutics has completed a Phase II study based on treatment of patients with COVID-19. Patients with mild-to-moderate COVID-19 experienced a 29% reduction in recovery time when receiving Combined Metabolic Cofactors Supplementation (CMCS) and standard of care of hydroxychloroquine compared to standard of care plus placebo in a Phase 2 clinical study. The CMCS consisting of L-serine, N-acetyl-L-cysteine (NAC), nicotinamide riboside (NR), and L-carnitine tartrate was designed to promote healthy mitochondrial function and reduced average recovery time to 6.6 days in comparison to average placebo recovery time of 9.3 days. COVID-19 has been associated with metabolic conditions such as hypertension, high blood sugar, obesity, high triglycerides and low HDL cholesterol, putting individuals with these conditions at greater risk for worse outcomes. The patients receiving the CMCS also experienced a significant improvement in liver function.
